Search This Blog

Monday, August 17, 2026

OmniAb ups 2026 year-end cash and cash equivalents guidance, announces Lilly ion channel deal

 

OmniAb raises 2026 year-end cash and cash equivalents guidance from $37–$41M to $49–$53M on technology licensing, announces Lilly ion channel deal with up to $370M milestones

  • Agreement with Eli Lilly is a global collaboration and license deal for an ion channel program.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)